UK buyout Cinven has been fined by the UK's competition regulator for conspiring to drive up the price of an anti-nausea drug by more than 700%. The post Cinven fined by UK competition watchdog for
Advent International and Singapore sovereign investor GIC have offered to buy booming rare-disease drugmaker Swedish Orphan Biovitrum in a deal valuing the business at about $8bn. The post Booming rare disease drugmaker SOBI valued at
Private equity major BC Partners has scored what is believed to be a 4x return through the €1.6bn sale of European generic drugmaker Pharmathen to Partners Group. The post BC Partners believed to score 4x
Drug discovery software provider Optibrium has been bought by Kester Capital in the firm's third deal since closing its £90m sophomore fund.
Iberian private equity investor GED Capital has bought four businesses through its GED VI España fund to create a new platform company of integrated services providers covering the needs of the whole drug life cycle.
French biotech company AlgoTherapeutix has raised €12m in a Series A round led by Bpifrance through its InnoBio 2 fund alongside co-investor Omnes.
Global private equity major KKR has agreed to acquire animal health-focused pharmaceutical business Argenta from the Tomlinson Group.
French pharmaceutical giant Sanofi has made a €50m investment in biotech and biopharma venture investment house Jeito Capital.
Private investment giant Ardian has bought a minority stake in H2 Pharma, a French specialist in the development and production of generic drugs.
Asian private equity investor PAG has reportedly teamed with CX Partners and Samara Capital to buy a controlling stake in Indian drug maker Anjan Drug.
SV Health Investors has hit a $265m final close for its first dedicated biotech fundraise.
European life science and healthcare investor LSP has led a €32m Series B financing round for VarmX, a biotech company focused on developing approaches for the reversal of anticoagulation.
Global private equity giant KKR has agreed to buy a 54% stake in Indian pharmaceutical business JB Chemicals, in a deal which could ultimately see it commit $500m to the company.
UK private equity house Inflexion has agreed to carve-out liquid pharma business Rosemont Pharmaceuticals from US-listed Perrigo.
Swiss contract research, development and manufacturing specialist Solvias has been bought by JLL Partners and Water Street Partners.
